Immunomodulatory peptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Identity and purity testing for thymosin alpha 1 relies mainly on reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatography separates the parent peptide from truncated or modified variants, while mass spectrometry confirms the expected molecular mass. Amino acid analysis and peptide mapping provide additional sequence confirmation. Counterion content, water content, and residual solvents are measured separately as part of specification testing. No single method captures every attribute, so laboratories combine several techniques.
The peptide lacks cysteine, methionine, and tryptophan, so disulfide scrambling and sulfur oxidation are not major degradation routes. Instead, aspartate residues can undergo isomerization or cyclization to succinimide intermediates, generating isoaspartate variants. Hydrolysis of peptide bonds also occurs slowly in solution. These changes may reduce biological activity even when the main peak remains detectable. Stability studies therefore track both potency and the appearance of related substances.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈3,108 Da | Synthetic 28-residue peptide |
| Amino acid count | 28 | N-terminal serine carries an acetyl group |
| Appearance | White to off-white powder | Lyophilized solid |
| Water solubility | Freely soluble | Dissolves in aqueous buffer |
| Common synonyms | Thymalfasin; Tα1 | Thymalfasin is the international nonproprietary name |
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Identity and purity are normally assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and truncation products. Mass spectrometry confirms molecular mass and detects modifications such as deamidation or oxidation. Amino acid analysis and peptide mapping provide additional sequence-level confirmation. For research material, a certificate of analysis typically reports these results together with water content and counter-ion identity, since the lyophilized powder is often supplied as an acetate or trifluoroacetate salt.
Several factors accelerate degradation: alkaline pH, elevated temperature, exposure to oxidants, and the presence of residual moisture. Deamidation of asparagine residues and oxidation of methionine are the most commonly reported degradation routes. Because the peptide lacks disulfide bonds, it does not undergo the thiol-related aggregation seen in some other biologics, but physical aggregation can still occur at high concentration. Stability data are product-specific, and extrapolating shelf life between formulations is not reliable.
=== Spoon test === The spoon test, developed in 1964 by Ernest Bors, relies on assessment of the smooth movement of the convex side of a spoon along the surface of the patient's skin. In patients with sudomotor dysfunction, the spoon will slide in a smooth and uninterrupted fashion. Conversely, the spoon's movement in normal controls will be frequently interrupted by the presence of sweat on the skin. The spoon test is inexpensive, easy to perform, but subjective and not quantitative.
== Further reading == Louis Beres, Apocalypse: Nuclear Catastrophe in World Politics. The risks and consequences of nuclear war and nuclear terrorism. University of Chicago Press, Chicago, 1980. ISBN 9780226043609 Laura Grego and David Wright, "Broken Shield: Missiles designed to destroy incoming nuclear warheads fail frequently in tests and could increase global risk of mass destruction", Scientific American, vol. 320, no. no. 6 (June 2019), pp. 62–67. "Nuclear-armed missiles are a political problem that technology cannot solve.... Current U.S. missile defense plans are being driven largely by technology, politics and fear. Missile defenses will not allow us to escape our vulnerability to nuclear weapons. Instead large-scale developments will create barriers to taking real steps toward reducing nuclear risks—by blocking further cuts in nuclear arsenals and potentially spurring new deployments." (p. 67.) Jessica T. Mathews, "The New Nuclear Threat", The New York Review of Books, vol. LXVII, no. 13 (20 August 2020), pp. 19–21. "[P]owerful reasons to doubt that there could be a limited nuclear war [include] those that emerge from any study of history, a knowledge of how humans act under pressure, or experience of government." (p. 20.) National Academies of Sciences, Engineering, and Medicine. 2025. Potential Environmental Effects of Nuclear War. The National Academies Press. "Possibility of Nuclear War in Asia: An Indian Perspective", a project of United Service Institution of India, USI, Discusses the possibility of a nuclear war in Asia from the Indian point of view.
Kenan Christopher Garcia (also known as K. Christopher Garcia) is an American scientist known for his research on the molecular and structural biology of cell surface receptors. Garcia is a professor in the Departments of Molecular and Cellular Physiology and Structural Biology at the Stanford University School of Medicine, an Investigator of the Howard Hughes Medical Institute and a member of the National Academies of Science and Medicine. In addition to his role at Stanford, Garcia is a co-founder of several biotechnology companies, including Alexo Therapeutics, Surrozen, and 3T Biosciences.
2 CH3CH=CH2 + 3 O2 + 2 NH3 → 2 N≡CCH=CH2 + 6 H2O In the production of acrylonitrile, a side product is acetonitrile. On an industrial scale, several derivatives of benzonitrile, phthalonitrile, as well as Isobutyronitrile are prepared by ammoxidation. The process is catalysed by metal oxides and is assumed to proceed via the imine. Ammoxidation is a heterogeneously catalyzed gas-phase reaction in which aliphatic or methyl-substituted aromatic compounds react with oxygen (air) and ammonia to form nitriles, with water as a by-product. Reaction temperatures exceed 300 °C, and oxides of vanadium, chromium, or molybdenum serve as catalysts. Acrylonitrile, an important precursor for polymer production (see Use section), is primarily manufactured by ammoxidation of propene. The principal industrial route to hydrogen cyanide is the Andrussov process, i.e., ammoxidation of methane over a platinum catalyst. However, a significant proportion of global hydrogen cyanide production arises as a by-product of acrylonitrile manufacture.
Sources: en.wikipedia.org
=== Hair loss disorder === The first LLLT (low-level laser device) device (at a wavelength of 635 nm) for androgenetic alopecia was approved by the FDA two decades ago. The FDA then approved a similar device (at a wavelength of 655 nm) for alopecia two years later, in 2009. Low-level laser therapy (LLLT) is the traditional FDA-approved therapy for hair loss disorders, while LEDT has become a more advanced treatment due to its safety and efficacy. The commonly used wavelengths targeting hair loss disorder are red and infrared. In-vivo studies show that the red-light LEDT at the wavelength of 655 nm contributes to dramatic improvements in the hair counts of androgenetic alopecia patients. A more recent study indicates a similar therapeutic effect of yellow-light LEDT on androgenetic alopecia and alopecia areata patients.
=== Health === In 2019, she was admitted to a local hospital after complaining of severe pain and illness. It was later revealed that she had caught a life-threatening bacterial infection, which was treated immediately. In February 2021, she underwent a removal of her breast implants and discussed her reason for choosing to remove her implants a year later in a YouTube video. In September 2024, Pansino posted an update on social media stating that she had been diagnosed with premenstrual dysphoric disorder (PMDD). She shared that it had been causing disruptions in her life that at times, had caused her to cancel all plans for weeks and that her symptoms had sent her to the emergency room twice. She also mentioned that she was working with a hormone specialist for treatment. In September 2025, Pansino posted an update on Facebook that her symptoms of PMDD were worsening to the point of causing disruptions in her daily life. As part of her post, she stated, "Recently, my own PMDD symptoms have gotten much worse and it has completely disrupted my ability to have a normal life. I am working with professionals to get onto a new treatment plan." She also posted that she was going to take a break from social media to focus on her treatment and that she intended to make an educational video on PMDD. In June 2025, Pansino posted on social media that she had a benign growth removed from her clavicle after finding the growth the previous year and having undergone an inconclusive biopsy.
=== Baháʼí Faith === While there are no dietary restrictions in the Baháʼí Faith, `Abdu'l-Bahá, the son of the religion's founder, noted that a vegetarian diet consisting of fruits and grains was desirable, except for people with a weak constitution or those that are sick. He stated that there are no requirements that Baháʼís become vegetarian, but that a future society should gradually become vegetarian. `Abdu'l-Bahá also stated that killing animals was contrary to compassion. While Shoghi Effendi, the head of the Bahá'í Faith in the first half of the 20th century, stated that a purely vegetarian diet would be preferable since it avoided killing animals, both he and the Universal House of Justice, the governing body of the Baháʼís have stated that these teachings do not constitute a Baháʼí practice and that Baháʼís can choose to eat whatever they wish but should be respectful of others' beliefs.
In the name NAD+, the superscripted plus sign indicates the positive formal charge on one of its nitrogen atoms. Some NAD is converted into the coenzyme nicotinamide adenine dinucleotide phosphate (NADP), whose chemistry largely parallels that of NAD, though its predominant role is as a coenzyme in anabolic metabolism. NADP is a reducing agent in anabolic reactions like the Calvin cycle and lipid and nucleic acid syntheses. NADP exists in two forms: NADP+, the oxidized form, and NADPH, the reduced form. NADP is similar to nicotinamide adenine dinucleotide (NAD), but NADP has a phosphate group at the C-2′ position of the adenosyl.
=== Economics === Concerns have been raised about the growing use of modafinil as a "smart drug" or cognitive enhancer among healthy individuals who use it with the aim to improve concentration and memory. In 2003, modafinil sales rose sharply amid concern that it was being used as a stimulant by people seeking an extra edge. The cost of modafinil has decreased substantially since generic versions became available in the US in 2012; retail prices for generic modafinil (30 tablets of 200 mg) range from approximately $20 to $45 with discount programs, compared to over $120 per month for brand-name Provigil in 2004. Global sales figures for modafinil have not been publicly disclosed. Modafinil sold under the brand name Provigil accounted for over 40% of Cephalon's global turnover for several years, according to data published in 2020.
Sources: en.wikipedia.org
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.
The lyophilized powder is kept refrigerated at 2 to 8 degrees Celsius and protected from light. Reconstituted solutions should be used promptly. Freezing and thawing repeatedly is avoided.